Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 6/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636643 | 0.72 | AR (0.56) | ARTRPA1 | |
| SCHEMBL2148589 | 0.68 | AR (0.48) | AR | |
| SCHEMBL20096687 | 0.65 | CACNA1H (0.41) | ARTRPA1 | |
| SCHEMBL20096569 | 0.65 | CACNA1H (0.41) | ARTRPA1 | |
| SCHEMBL1636551 | 0.65 | AR (0.44) | AR | |
| SCHEMBL31679092 | 0.63 | NPC1 (0.63) | HDAC3HDAC7HDAC10HDAC6PARP1 | |
| SCHEMBL4117692 | 0.63 | NPC1 (0.63) | HDAC3HDAC7HDAC10HDAC6PARP1 | |
| SCHEMBL1260022 | 0.63 | CACNA1H (0.37) | ARTRPA1 | |
| SCHEMBL1635569 | 0.63 | AR (0.40) | ARTRPA1MCHR1 | |
| SCHEMBL24049714 | 0.62 | HDAC3 (0.61) | HDAC3HDAC7HDAC10HDAC6PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932399-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | HDAC3 124/4885HDAC7 187/4885HDAC10 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.